IMGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
text size: T | T
Back to Snapshot
Company Description

Contact Info

830 Winter Street

Waltham, MA 02451

United States

Phone: 781-895-0600

Fax:

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. Its ADC technology is designed to enable the creation of well-tolerated anticancer products. An ADC with its technology comprises an antibody that binds primarily to an antigen target found on the surface of cancer cells with one of its proprietary, potent cancer-killing agents attached. Its antibody component enables an ADC compound to bind specifically to a tumor cell with the target antigen on its surface, which the cancer-killing agent can then kill. Product Candidates Mirvetuximab Soravtansine Mirvetuximab soravtansine is the ADC to target folate-receptor alpha (FRa), which is expressed on various ovarian cancers and some other types of solid tumors. It is a potential treatment for FRa-positive solid tumors, including ovarian cancer and has been granted orphan drug status for ovarian cancer in the U.S. and the European Union (the EU). Following a meeting with the U.S. Food and Drug Administration (FDA) in July 2016, the company is initiating a Phase 3 registration trial, FORWARD I, with mirvetuximab soravtansine for use as single-agent therapy to treat patients with platinum-resistant ovarian cancer whose tumors express high or medium levels of FRa and who have received up to three prior treatment regimens. Additionally, it is accruing patients in a companion study, FORWARD II, to evaluate mirvetuximab soravtansine in combination regimens to expand the number of patients with ovarian cancer eligible for treatment with the ADC. IMGN779 and IMGN632 – ADCs for acute myeloid leukemia (AML) The company has built a productive platform that continues to generate proprietary ADCs, including IMGN779, its CD33-targeting product candidate for AML. IMGN779 integrates one of its DNA-alkylating IGN payload agents and is progressing through dose escalation in a Phase 1 trial in AML. The company is also advancing IMGN632, a preclinical CD123-targeting ADC that uses a potent IGN payload agent with an engineered linker and novel antibody, which it is developing for hematological malignancies, including AML. IMGN529 and coltuximab ravtansine – novel ADCs for B-cell malignancies The company’s CD37-targeting ADC, IMGN529, has demonstrated single-agent activity in relapsed/refractory DLBCL (a type of non-Hodgkin lymphoma) in Phase 1 testing and synergy with rituximab in preclinical testing. IMGN529 is in Phase 2 clinical testing in combination with rituximab. This novel ADC has orphan drug status for DLBCL in the U.S. The company’s CD19-targeting ADC, coltuximab ravtansine, has demonstrated single-agent, proof-of-concept activity in Phase 2 clinical testing. This product candidate is best advanced in a combination regimen. Partners The company’s partners include Amgen; Bayer HealthCare AG; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; Roche; Sanofi; and Takeda Pharmaceutical Company Limited. It also has a research agreement with CytomX Therapeutics, Inc. that allows each company to develop product candidates to a specified number of cancer targets using CytomX’s Probody antibody-masking technology with the company’s payload agents and engineered linkers. Sanofi Collaboration Agreement: In 2003, the company entered into a collaboration agreement with Sanofi (formerly Aventis) to discover, develop and commercialize antibody-based products. The collaboration agreement provides Sanofi with worldwide development and commercialization rights to new antibody-based products directed to targets that are included in the collaboration, including the exclusive right to use its maytansinoid ADC technology in the creation of products developed to these targets. Intellectual Property As of June 30, 2016, the company’s patent portfolio had a total of 765 issued patents worldwide and 749 pending patent applications worldwide. Research and Development During the year ended June 30, 2016, the company spent approximately $148.1 million on research and development activities. History ImmunoGen, Inc. was founded in 1981. The company was incorporated in Massachusetts in 1981.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

IMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMGN.
View Industry Companies
 

Industry Analysis

IMGN

Industry Average

Valuation IMGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact IMMUNOGEN INC, please visit www.immunogen.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.